Immunomodulation for Pompe Disease with high sustained antibodies against enzyme replacement therapy

Blasco-Alonso, Javier; Gil-Gómez, Raquel; Jurado, Alfonso Lendínez; Macías, Raquel Yahyaoui

doi:10.1016/j.medcle.2020.09.015

array:24 ["pii" => "S2387020621005210" "issn" => "23870206" "doi" => "10.1016/j.medcle.2020.09.015" "estado" => "S300" "fechaPublicacion" => "2021-10-22" "aid" => "5473" "copyright" => "Elsevier España, S.L.U.. All rights reserved" "copyrightAnyo" => "2020" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Med Clin. 2021;157:403-5" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "en" => array:19 [ "pii" => "S0025775320307557" "issn" => "00257753" "doi" => "10.1016/j.medcli.2020.09.017" "estado" => "S300" "fechaPublicacion" => "2021-10-22" "aid" => "5473" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Med Clin. 2021;157:403-5" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "Letter to the Editor" "titulo" => "Immunomodulation for Pompe Disease with high sustained antibodies against enzyme replacement therapy" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "403" "paginaFinal" => "405" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Inmunomodulación con altos títulos mantenidos de anticuerpos contra terapia de reemplazo enzimático en la enfermedad de Pompe" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 3028 "Ancho" => 2167 "Tamanyo" => 376924 ] ] "descripcion" => array:1 [ "en" => "Measurement of left ventricular index, Glc4 levels and Anti-rhGAA antibody titers in different moments before and after administration of immunomodulatory agents." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Javier Blasco-Alonso, Raquel Gil-Gómez, Alfonso Lendínez Jurado, Raquel Yahyaoui Macías" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Javier" "apellidos" => "Blasco-Alonso" ] 1 => array:2 [ "nombre" => "Raquel" "apellidos" => "Gil-Gómez" ] 2 => array:2 [ "nombre" => "Alfonso Lendínez" "apellidos" => "Jurado" ] 3 => array:2 [ "nombre" => "Raquel Yahyaoui" "apellidos" => "Macías" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2387020621005210" "doi" => "10.1016/j.medcle.2020.09.015" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020621005210?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775320307557?idApp=UINPBA00004N" "url" => "/00257753/0000015700000008/v1_202110170505/S0025775320307557/v1_202110170505/en/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2387020621005209" "issn" => "23870206" "doi" => "10.1016/j.medcle.2020.09.014" "estado" => "S300" "fechaPublicacion" => "2021-10-22" "aid" => "5471" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Med Clin. 2021;157:405-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Letter to the Editor" "titulo" => "Major orthopedic surgery in a patient with fibromuscular dysplasia in the right renal artery and mild hemophilia A: First case reported" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "405" "paginaFinal" => "406" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Paciente con displasia fibromuscular en arteria renal derecha y hemofilia A leve intervenido de cirugía ortopédica mayor: primer caso reportado" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Mariana Fernández Caballero, Fernando Collado, José-Tomás Navarro" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Mariana" "apellidos" => "Fernández Caballero" ] 1 => array:2 [ "nombre" => "Fernando" "apellidos" => "Collado" ] 2 => array:2 [ "nombre" => "José-Tomás" "apellidos" => "Navarro" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S0025775320307533" "doi" => "10.1016/j.medcli.2020.09.015" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775320307533?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020621005209?idApp=UINPBA00004N" "url" => "/23870206/0000015700000008/v1_202110160801/S2387020621005209/v1_202110160801/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2387020621005064" "issn" => "23870206" "doi" => "10.1016/j.medcle.2020.09.011" "estado" => "S300" "fechaPublicacion" => "2021-10-22" "aid" => "5443" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Med Clin. 2021;157:402-3" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Letter to the Editor" "titulo" => "Hyperammonemic encephalopathy in a patient with hereditary hemorrhagic telangiectasia" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "402" "paginaFinal" => "403" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Encefalopatía hiperamoniémica en una paciente con telangiectasia hemorrágica hereditaria" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Joana de Miguel Landiríbar, Oihane Orokieta Rincón, Alfonso Gutiérrez Macías" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Joana" "apellidos" => "de Miguel Landiríbar" ] 1 => array:2 [ "nombre" => "Oihane" "apellidos" => "Orokieta Rincón" ] 2 => array:2 [ "nombre" => "Alfonso" "apellidos" => "Gutiérrez Macías" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0025775320307259" "doi" => "10.1016/j.medcli.2020.09.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775320307259?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020621005064?idApp=UINPBA00004N" "url" => "/23870206/0000015700000008/v1_202110160801/S2387020621005064/v1_202110160801/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "Letter to the Editor" "titulo" => "Immunomodulation for Pompe Disease with high sustained antibodies against enzyme replacement therapy" "tieneTextoCompleto" => true "saludo" => "Dear Editor:" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "403" "paginaFinal" => "405" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Javier Blasco-Alonso, Raquel Gil-Gómez, Alfonso Lendínez Jurado, Raquel Yahyaoui Macías" "autores" => array:4 [ 0 => array:4 [ "nombre" => "Javier" "apellidos" => "Blasco-Alonso" "email" => array:1 [ 0 => "javierblascoalonso@yahoo.es" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Raquel" "apellidos" => "Gil-Gómez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] 2 => array:3 [ "nombre" => "Alfonso Lendínez" "apellidos" => "Jurado" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "Raquel Yahyaoui" "apellidos" => "Macías" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "d" "identificador" => "aff0020" ] ] ] ] "afiliaciones" => array:4 [ 0 => array:3 [ "entidad" => "UGC Pediatría. Hospital Materno-Infantil, Hospital Regional Universitario de Málaga, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Grupo IBIMA Multidisciplinar de Investigación Pediátrica, Universidad de Málaga, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Unidad de Gestión Clínica de Cuidados Críticos y Urgencias de Pediatría, Hospital Materno-Infantil, Hospital Regional Universitario de Málaga, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Unidad de Gestión Clínica Laboratorio, Hospital Materno-Infantil, Hospital Regional Universitario de Málaga, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Inmunomodulación con altos títulos mantenidos de anticuerpos contra terapia de reemplazo enzimático en la enfermedad de Pompe" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 3028 "Ancho" => 2167 "Tamanyo" => 376924 ] ] "descripcion" => array:1 [ "en" => "Measurement of left ventricular index, Glc4 levels and Anti-rhGAA antibody titers in different moments before and after administration of immunomodulatory agents." ] ] ] "textoCompleto" => "Enzyme replacement therapies (ERT) have prolonged the survival and improved clinical outcomes of patients suffering from a multitude of disorders. Some of the Infantile Pompe Disease (IPD) patients treated with alglucosidase alfa develop anti-rhGAA IgG antibodies<a class="elsevierStyleCrossRef" href="#bib0030">1</a> and the longer term therapeutic efficacy of alglucosidase alfa appears to be more strongly associated with them. Several investigators have unsuccessfully made attempts<a class="elsevierStyleCrossRefs" href="#bib0035">2–5</a> in IPD treated with therapeutic proteins to either achieve immune tolerance or mitigate the immune response, including increasing the dose of therapeutic protein and implementing various drug regimens.Here, we report the first successful achievement in Spain of true immune tolerance to ongoing ERT in a IPD girl with high sustained antibody titles (HSAT).Patient is a Chinese descent girl who presented at age 15 days with normal motor development and a cardiac murmur; echocardiogram showed significant biventricular hypertrophy. She was diagnosed with IPD at age 1 month and ERT was started at 20mg/kg biweekly. Later on, she was cataloged as CRIM-negative IPD at age 4 months. Initial Glc4 levels were 21.8mmol/mol creatinin at age 1 month.She initially benefited clinically from ERT, as evidenced by reduction in left ventricular mass index (LVMI) from 107g/m2 to 94g/m2 at 6 months of age) and maintaining normal Gross Motor Function (level 1). She maintained adequate physical activity and progressed in developmental motor milestones; an initial phase of improvement in LVMI (100g/m2, 20 months, to 62.3g/m2, 24 months) was also noted. At 24 months of age, she first developed HSAT (1/700) and began generalized hypotonia, tongue protrusion, facial myopathy, and cardiomegaly (LVMI values deteriorated from 62.3g/m2 at 24 months of age, to 139g/m2 at 30 months and 200.9g/m2 at 36 months); however, she did not need any respiratory support and tolerated normal oral feeds and was growing normally (62 percentile of weight and height at 33 percentile). For several weeks, ERT was increased from 20 to 35mg/kg/dose with no difference in clinical or functional evaluation. Her antibody titers continued to rise, peaking at 1/1600 at 36 months of age, accompanied by increased urinary Glc4 levels (19.4mmol/mol creatinine at 6 months, to 21.5mmol/mol creatinine at 3 years). At age 41 months, she was hospitalized in the intensive care unit because of an upper respiratory tract infection, and she became ventilator dependent for 2 months and required nasogastric tube feeds. After improvement from acute phase and ventilation withdrawal she was discharged with a Gross Motor Function classification system at level 3 and an increase in antibody titers up to 1/32,000.An ITI protocol was initiated at 49 months of age (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>), with intravenous rituximab (4 doses) and subcutaneous methotrexate (9 doses) for 6 weeks and monthly immunoglobulin infusion for 5 months, resulting in a reduction in titers (1/800 after 6 weeks of treatment, 1/200 after 32 weeks, 1/100 after 112 weeks) and an improvement in gross motor function indexes (level 2), although maintaining facial amymia and easy tiredness in school activities. Urinary Glc4 levels were 20mmol/mol creatinine and LVMI was 104g/m2 at 24 weeks after the end of ITI. ERT continued to be successfully administered afterwards.<elsevierMultimedia ident="fig0005"></elsevierMultimedia>Although the ITI treatment described here prolongs survival and improves significant overall clinical outcomes, closer examination clearly demonstrates residual muscle weakness and gross motor function below age-appropriate levels along with feeding difficulties.We believe our immune-modulating strategy has potentially broader clinical implications. Use of the protocol described herein is designed to take place over a relatively brief period of time. This protocol has helped lower antibody titers in these ill IPD patient; however, there is still a need for development of a less extensive protocol with agents that are antigen specific to reduce the immune response. Additional research will be needed to establish the proper dosing regimen of immune-suppressive agents in Pompe and other conditions and the optimal way to taper the maintenance regimen following rituximab and/or other immunomodulatory agent treatments to ensure long-lasting tolerance. Our protocol was well tolerated, safe, and effective in reducing a life-threatening immune response and was successful in inducing long-term immune tolerance.<elsevierMultimedia ident="tb0005"></elsevierMultimedia>" "pdfFichero" => "main.pdf" "tienePdf" => true "multimedia" => array:2 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 3028 "Ancho" => 2167 "Tamanyo" => 376924 ] ] "descripcion" => array:1 [ "en" => "Measurement of left ventricular index, Glc4 levels and Anti-rhGAA antibody titers in different moments before and after administration of immunomodulatory agents." ] ] 1 => array:5 [ "identificador" => "tb0005" "tipo" => "MULTIMEDIATEXTO" "mostrarFloat" => false "mostrarDisplay" => true "texto" => array:1 [ "textoCompleto" => "What's already known on this feature?Several immune tolerance regimes have been described but always in very few patients, none of them in Spain to the best of our knowledge.What's new on this feature?Although clinical experience and current literature on the use of ITI protocols are greatly limited, success is more likely when immune modulation is previously demonstrated." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0030" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical guidelines for infantile-onset Pompe disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.I. Pascual-Pascual" 1 => "A. Nascimento" 2 => "C.M. Fernandez-Llamazares" 3 => "C. Medrano-Lopez" 4 => "E. Villalobos-Pinto" 5 => "M. Martinez-Moreno" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Rev Neurol" "fecha" => "2016" "volumen" => "63" "paginaInicial" => "269" "paginaFinal" => "279" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27600742" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0035" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Immune modulation in Pompe disease treated with enzyme replacement therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S.G. Banugaria" 1 => "T.T. Patel" 2 => "P.S. Kishnani" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1586/eci.12.40" "Revista" => array:6 [ "tituloSerie" => "Expert Rev Clin Immunol" "fecha" => "2012" "volumen" => "8" "paginaInicial" => "497" "paginaFinal" => "499" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22992140" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0040" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Y.H. Messinger" 1 => "N.J. Mendelsohn" 2 => "W. Rhead" 3 => "D. Dimmock" 4 => "E. Hershkovitz" 5 => "M. Champion" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/gim.2011.4" "Revista" => array:6 [ "tituloSerie" => "Genet Med" "fecha" => "2012" "volumen" => "14" "paginaInicial" => "135" "paginaFinal" => "142" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22237443" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0045" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.E. Elder" 1 => "S. Nayak" 2 => "S.W. Collins" 3 => "L.A. Lawson" 4 => "J.S. Kelley" 5 => "R.W. Herzog" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jpeds.2013.06.055" "Revista" => array:4 [ "tituloSerie" => "J Pediatr" "fecha" => "2013" "volumen" => "163" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23958115" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0050" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.G. Banugaria" 1 => "S.N. Prater" 2 => "J.K. McGann" 3 => "J.D. Feldman" 4 => "J.A. Tannenbaum" 5 => "C. Bailey" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/gim.2012.110" "Revista" => array:6 [ "tituloSerie" => "Genet Med" "fecha" => "2013" "volumen" => "15" "paginaInicial" => "123" "paginaFinal" => "131" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23060045" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/23870206/0000015700000008/v1_202110160801/S2387020621005210/v1_202110160801/en/main.assets" "Apartado" => array:4 [ "identificador" => "43309" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Letters to the Editor" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/23870206/0000015700000008/v1_202110160801/S2387020621005210/v1_202110160801/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020621005210?idApp=UINPBA00004N"]

ISSN: 2387-0206

Launched in 1943, Medicina Clínica is a fortnightly journal aimed at the promotion of clinical research and practice among internal medicine and other specialists. The key characteristics of Medicina Clínica are the scientific and methodological rigor of its manuscripts, the topicality of its contents, and, especially, its practical focus with highly useful information for clinical practice. Medicina Clínica is predominantly interested in publishing original research manuscripts, which are rigorously selected according to their quality, originality, and interest, and also in continued medical education-oriented manuscripts, which are commissioned by the journal to relevant authors (Editorials, Reviews, and Diagnosis and Treatment). These manuscripts contain updated topics with a major clinical or conceptual relevance in modern medicine. The journal adheres to the standards of academic research publications in all aspects including peer-review and ethical principles. Medicina Clínica is included in the General and Internal Medicine category of Thomson Reuters.

See more Open Access Option

Indexed in:

Current Contents/Clinical Medicine, Journal Citation Reports, SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, MEDES, PASCAL, SCOPUS, SciVerse ScienceDirect

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2023

2.6

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

3.1

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.371

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.511

View more metrics

Journal Information

Previous article | Next article

Vol. 157. Issue 8.

Pages 403-405 (October 2021)

Export reference

Download PDF

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)

Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”

Subscribe to

Medicina Clínica (English Edition)

More information

Purchase

Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now

Contact

Phone for subscriptions and reporting of errors

From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.

Calls from Spain

932 415 960

Calls from outside Spain

+34 932 415 960

E-mail

atencionalcliente@elsevier.com

Publish in

Medicina Clínica

Tools

Free access articles

Associations of physical activity, sedentary time,...

Med Clin. 2024;163:327-35

Burden of COVID-19 variant omicron in immunocompromised...

Med Clin. 2024;163:347-59

Raynaud phenomenon in a baseball...

Med Clin. 2024;163:e79

Medicina Clínica (English Edition) follows the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals

Indexed in:

Follow us:

Subscribe:

Article

Subscribe to our newsletter